Activation of Constitutive Androstane Receptor (CAR) in mice results in maintained biliary excretion of bile acids despite a marked decrease of bile acids in liver

Toxicological Sciences

Volumn 151, Issue 2, 2016, Pages 403-418

  Lickteig, Andrew J ^a   Csanaky, Iván L ^a,b,c   Pratt Hyatt, Matthew ^a   Klaassen, Curtis D ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b CHILDREN S MERCY HOSPITAL   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Bile acids; Biliary excretion; Constitutive androstane receptor; Muricholic acid; Taurocholic acid; TCPOBOP

Indexed keywords

1,4 BIS(3,5 DICHLORO 2 PYRIDYLOXY)BENZENE; BILE ACID; CHOLESTEROL 7ALPHA MONOOXYGENASE; CONSTITUTIVE ANDROSTANE RECEPTOR; MESSENGER RNA; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 3; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; TAUROCHOLIC ACID; 1,4-BIS(2-(3,5-DICHLOROPYRIDYLOXY))BENZENE; CARRIER PROTEIN; CELL RECEPTOR; CYP7A1 PROTEIN, MOUSE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 15, MOUSE; PYRIDINE DERIVATIVE; STEROID 12ALPHA MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE COMPOSITION; BILE FLOW; BILIARY EXCRETION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; LIMIT OF QUANTITATION; LIVER; LIVER WEIGHT; MALE; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; UPREGULATION; AGONISTS; ANIMAL; BILE; BLOOD; C57BL MOUSE; DRUG EFFECTS; GENETICS; ILEUM; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; BILE; BILE ACIDS AND SALTS; CHOLESTEROL 7-ALPHA-HYDROXYLASE; FEMALE; FIBROBLAST GROWTH FACTORS; HEPATOBILIARY ELIMINATION; ILEUM; LIVER; MALE; MEMBRANE TRANSPORT PROTEINS; MICE, INBRED C57BL; PYRIDINES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER; SIGNAL TRANSDUCTION; STEROID 12-ALPHA-HYDROXYLASE;

EID: 84978998604     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfw054     Document Type: Article

References (86)

1. Alnouti, Y., Csanaky, I. L., and Klaassen, C. D. (2008). Quantitative-profiling of bile acids and their conjugates in mouse liver, bile, plasma, and urine using LC-MS/MS. J. Chromatogr. B, Analyt. Technol. Biomed. Life Sci. 873, 209-217
2. Assem, M., Schuetz, E. G., Leggas, M., Sun, D., Yasuda, K., Reid, G., Zelcer, N., Adachi, M., Strom, S., Evans, R. M., et al. (2004). Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J. Biol. Chem. 279, 22250-22257
3. Bays, H. E., Goldberg, R. B., Truitt, K. E., and Jones, M. R. (2008). Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: Glucose and lipid effects. Arch. Intern. Med. 168, 1975-1983
4. Beilke, L. D., Aleksunes, L. M., Holland, R. D., Besselsen, D. G., Beger, R. D., Klaassen, C. D., and Cherrington, N. J. (2009). Constitutive androstane receptor-mediated changes in bile acid composition contributes to hepatoprotection from lithocholic acid-induced liver injury in mice. Drug Metab. Dispos. 37, 1035-1045
5. Berthelot, P., Erlinger, S., Dhumeaux, D., and Preaux, A. M. (1970). Mechanism of phenobarbital-induced hypercholeresis in the rat. Am. J. Physiol. 219, 809-813
6. Beysen, C., Murphy, E. J., Deines, K., Chan, M., Tsang, E., Glass, A., Turner, S. M., Protasio, J., Riiff, T., and Hellerstein, M. K. (2012). Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: A randomised controlled study. Diabetologia 55, 432-442
7. Bhamidimarri, K. R., and Schiff, E. (2013). Drug-induced cholestasis. Clin. Liver Dis. 17, 519-531. vii
8. Billington, D., Evans, C. E., Godfrey, P. P., and Coleman, R. (1980). Effects of bile salts on the plasma membranes of isolated rat hepatocytes. Biochem. J. 188, 321-327
9. Buckley, D. B., and Klaassen, C. D. (2009). Induction of mouse UDP-glucuronosyltransferase mRNA expression in liver and intestine by activators of aryl-hydrocarbon receptor, constitutive androstane receptor, pregnane X receptor, peroxisome proliferator-activated receptor alpha, and nuclear factor erythroid 2-related factor 2. Drug Metab. Dispos. 37, 847-856
10. Carey, M. C., and Small, D. M. (1972). Micelle formation by bile salts. Physical-chemical and thermodynamic considerations. Arch. Intern. Med. 130, 506-527
11. Chiang, J. Y. (2003). Bile acid regulation of hepatic physiology: III. Bile acids and nuclear receptors. Am. J. Physiol. Gastrointest. Liver Physiol. 284, G349-G356
12. Csanaky, I. L., Lu, H., Zhang, Y., Ogura, K., Choudhuri, S., and Klaassen, C. D. (2011). Organic anion-transporting polypeptide 1b2 (Oatp1b2) is important for the hepatic uptake of unconjugated bile acids: Studies in Oatp1b2-null mice. Hepatology 53, 272-281
13. Cui, J. Y., Aleksunes, L. M., Tanaka, Y., Fu, Z. D., Guo, Y., Guo, G. L., Lu, H., Zhong, X. B., and Klaassen, C. D. (2012). Bile acids via Fxr initiate the expression of major transporters involved in the enterohepatic circulation of bile acids in newborn mice. Am. J. Physiol. Gastrointest. Liver Physiol. 302, G979-G996
14. Danielsson, H., Eneroth, P., Hellstrom, K., Lindstedt, S., and Sjovall, J. (1963). On the turnover and excretory products of cholic and chenodeoxycholic acid in man. J. Biol. Chem. 238, 2299-2304
15. Daugherty, C. C., Setchell, K. D., Heubi, J. E., and Balistreri, W. F. (1993). Resolution of liver biopsy alterations in three siblings with bile acid treatment of an inborn error of bile acid metabolism (delta 4-3-oxosteroid 5 beta-reductase deficiency). Hepatology 18, 1096-1101
16. Fonseca, V. A., Rosenstock, J., Wang, A. C., Truitt, K. E., and Jones, M. R. (2008). Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 31, 1479-1484
17. Garg, A., and Grundy, S. M. (1994). Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann. Intern. Med. 121, 416-422
18. Gerloff, T., Stieger, B., Hagenbuch, B., Madon, J., Landmann, L., Roth, J., Hofmann, A. F., and Meier, P. J. (1998). The sister of Pglycoprotein represents the canalicular bile salt export pump of mammalian liver. J. Biol. Chem. 273, 10046-10050
19. Goldberg, R. B., Fonseca, V. A., Truitt, K. E., and Jones, M. R. (2008). Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch. Intern. Med. 168, 1531-1540
20. Goodwin, B., Jones, S. A., Price, R. R., Watson, M. A., McKee, D. D., Moore, L. B., Galardi, C., Wilson, J. G., Lewis, M. C., Roth, M. E., et al. (2000). A regulatory cascade of the nuclear receptors Fxr, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell 6, 517-526
21. Guarino, M. P., Cocca, S., Altomare, A., Emerenziani, S., and Cicala, M. (2013). Ursodeoxycholic acid therapy in gallbladder disease, a story not yet completed. World J. Gastroenterol.19, 5029-5034
22. Guo, G. L., Lambert, G., Negishi, M., Ward, J. M., Brewer, H. B., Jr., Kliewer, S. A., Gonzalez, F. J., and Sinal, C. J. (2003). Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity. J. Biol. Chem. 278, 45062-45071
23. Haeusler, R. A., Astiarraga, B., Camastra, S., Accili, D., and Ferrannini, E. (2013). Human insulin resistance is associated with increased plasma levels of 12alpha-hydroxylated bile acids. Diabetes 62, 4184-4191
24. Halilbasic, E., Baghdasaryan, A., and Trauner, M. (2013). Nuclear receptors as drug targets in cholestatic liver diseases. Clin. Liver Dis. 17, 161-189
25. Heubi, J. E., Setchell, K. D., Jha, P., Buckley, D., Zhang, W., Rosenthal, P., Potter, C., Horslen, S., and Suskind, D. (2015). Treatment of bile acid amidation defects with glycocholic acid. Hepatology 61, 268-274
26. Heuman, D. M. (1989). Quantitative estimation of the hydrophilic-hydrophobic balance of mixed bile salt solutions. J. Lipid Res. 30, 719-730
27. Hofmann, A. F. (1984). Chemistry and enterohepatic circulation of bile acids. Hepatology 4, 4S-14S
28. Hofmann, A. F., and Hagey, L. R. (2008). Bile acids: Chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell. Mol. Life Sci. 65, 2461-2483
29. Hofmann, A. F., and Roda, A. (1984). Physicochemical properties of bile acids and their relationship to biological properties: An overview of the problem. J. Lipid Res. 25, 1477-1489
30. Holt, J. A., Luo, G., Billin, A. N., Bisi, J., McNeill, Y. Y., Kozarsky, K. F., Donahee, M., Wang, D. Y., Mansfield, T. A., Kliewer, S. A., et al. (2003). Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 17, 1581-1591
31. Honkakoski, P., Zelko, I., Sueyoshi, T., and Negishi, M. (1998). The nuclear orphan receptor CAR-retinoid X receptor heterodimer activates the phenobarbital-responsive enhancer module of the CYP2B gene. Mol. Cell Biol. 18, 5652-5658
32. Hosseinpour, F., Moore, R., Negishi, M., and Sueyoshi, T. (2005). Serine 202 regulates the nuclear translocation of constitutive active/androstane receptor. Mol. Pharmacol. 69, 1095-1102
33. Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C. L., McDonald, J. G., Luo, G., Jones, S. A., Goodwin, B., Richardson, J. A., et al. (2005). Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2, 217-225
34. Kakizaki, S., Yamamoto, Y., Ueda, A., Moore, R., Sueyoshi, T., and Negishi, M. (2003). Phenobarbital induction of drug/steroidmetabolizing enzymes and nuclear receptor CAR. Biochim. Biophys. Acta 1619, 239-242
35. Kawamoto, T., Sueyoshi, T., Zelko, I., Moore, R., Washburn, K., and Negishi, M. (1999). Phenobarbital-responsive nuclear translocation of the receptor CAR in induction of the CYP2B gene. Mol. Cell Biol. 19, 6318-6322
36. Klaassen, C. D. (1969). Biliary flow after microsomal enzyme induction. J. Pharmacol. Exp. Ther. 168, 218-223
37. Klaassen, C. D. (1970). Effects of phenobarbital on the plasma disappearance and biliary excretion of drugs in rats. J. Pharmacol. Exp. Ther. 175, 289-300
38. Klaassen, C. D. (1971a). Does bile acid secretion determine canalicular bile production in rats? Am. J. Physiol. 220, 667-673
39. Klaassen, C. D. (1971b). Studies on the increased biliary flow produced by phenobarbital in rats. J. Pharmacol. Exp. Ther. 176, 743-751
40. Klaassen, C. D., and Plaa, G. L. (1968). Studies on the mechanism of phenobarbital-enhanced sulfobromophthalein disappearance. J. Pharmacol. Exp. Ther. 161, 361-366
41. Kong, B., Wang, L., Chiang, J. Y., Zhang, Y., Klaassen, C. D., and Guo, G. L. (2012). Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. Hepatology 56, 1034-1043
42. Li-Hawkins, J., Gafvels, M., Olin, M., Lund, E. G., Andersson, U., Schuster, G., Bjorkhem, I., Russell, D. W., and Eggertsen, G. (2002). Cholic acid mediates negative feedback regulation of bile acid synthesis in mice. J. Clin. Invest. 110, 1191-1200
43. Lindstedt, S. (1957). The turnover of cholic acid in man: Bile acids and steroids. Acta Physiol. Scand. 40, 1-9
44. Lu, T. T., Makishima, M., Repa, J. J., Schoonjans, K., Kerr, T. A., Auwerx, J., and Mangelsdorf, D. J. (2000). Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol. Cell 6, 507-515
45. Madan, A., Graham, R. A., Carroll, K. M., Mudra, D. R., Burton, L. A., Krueger, L. A., Downey, A. D., Czerwinski, M., Forster, J., Ribadeneira, M. D., et al. (2003). Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab. Dispos. 31, 421-431
46. Madon, J., Eckhardt, U., Gerloff, T., Stieger, B., and Meier, P. J. (1997). Functional expression of the rat liver canalicular isoform of the multidrug resistance-associated protein. FEBS Lett. 406, 75-78
47. Maher, J. M., Cheng, X., Slitt, A. L., Dieter, M. Z., and Klaassen, C. D. (2005). Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver. Drug Metab. Dispos. 33, 956-962
48. May, G. R., Sutherland, L. R., and Shaffer, E. A. (1993). Efficacy of bile acid therapy for gallstone dissolution: A meta-analysis of randomized trials. Aliment. Pharmacol. Ther. 7, 139-148
49. Miao, J., Fang, S., Bae, Y., and Kemper, J. K. (2006). Functional inhibitory cross-talk between constitutive androstane receptor and hepatic nuclear factor-4 in hepatic lipid/glucose metabolism is mediated by competition for binding to the DR1 motif and to the common coactivators, GRIP-1 and PGC-1alpha. J. Biol. Chem. 281, 14537-14546
50. Monte, M. J., Marin, J. J., Antelo, A., and Vazquez-Tato, J. (2009). Bile acids: Chemistry, physiology, and pathophysiology. World J. Gastroenterol. 15, 804-816
51. Mutoh, S., Osabe, M., Inoue, K., Moore, R., Pedersen, L., Perera, L., Rebolloso, Y., Sueyoshi, T., and Negishi, M. (2009). Dephosphorylation of threonine 38 is required for nuclear translocation and activation of human xenobiotic receptor CAR (NR1I3). J. Biol. Chem. 284, 34785-34792
52. Okuda, H., Sorrentino, D., Alpini, G., Tavoloni, N., Jones, M. J., Kiang, C. L., and Berk, P. D. (1988). Bile acid secretion and pool size during phenobarbital induced hypercholeresis. Proc. Soc. Exp. Biol. Med. Exp. Biol. Med. 187, 202-208
53. Orekoya, O., McLaughlin, J., Leitao, E., Johns, W., Lal, S., and Paine, P. (2015). Quantifying bile acid malabsorption helps predict response and tailor sequestrant therapy. Clin. Med. (London, England) 15, 252-257
54. Palmer, R. H. (1972). Bile acids, liver injury, and liver disease. Arch. Intern. Med. 130, 606-617
55. Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G., Consler, T. G., Kliewer, S. A., Stimmel, J. B., Willson, T. M., Zavacki, A. M., Moore, D. D., and., et al. (1999). Bile acids: Natural ligands for an orphan nuclear receptor. Science 284, 1365-1368
56. Paumgartner, G., Horak, W., Probst, P., and Grabner, G. (1971). Effect of phenobarbital on bile flow and bile salt excretion in the rat. Naunyn-Schmied. Archiv. Pharmacol. 270, 98-101
57. Perez, M. J., and Briz, O. (2009). Bile-acid-induced cell injury and protection. World J. Gastroenterol. 15, 1677-1689
58. Poland, A., Mak, I., Glover, E., Boatman, R. J., Ebetino, F. H., and Kende, A. S. (1980). 1,4-Bis[2-(3,5-dichloropyridyloxy)]benzene, a potent phenobarbital-like inducer of microsomal monooxygenase activity. Mol. Pharmacol. 18, 571-580
59. Poland, A., Mak, I., and Glover, E. (1981). Species differences in responsiveness to 1,4-bis[2-(3,5-dichloropyridyloxy)]-benzene, a potent phenobarbital-like inducer of microsomal monooxygenase activity. Mol. Pharmacol. 20, 442-450
60. Roberts, R. J., and Plaa, G. L. (1967). Effect of phenobarbital on the excretion of an exogenous bilirubin load. Biochem. Pharmacol. 16, 827-835
61. Rockwell, C. E., Zhang, M., Fields, P. E., and Klaassen, C. D. (2012). Th2 skewing by activation of Nrf2 in CD4(+) T cells. J. Immunol. 188, 1630-1637
62. Russell, D. W. (2003). The enzymes, regulation, and genetics of bile acid synthesis. Ann. Rev. Biochem. 72, 137-174
63. Saini, S. P., Sonoda, J., Xu, L., Toma, D., Uppal, H., Mu, Y., Ren, S., Moore, D. D., Evans, R. M., and Xie, W. (2004). A novel constitutive androstane receptor-mediated and CYP3A-independent pathway of bile acid detoxification. Mol. Pharmacol. 65, 292-300
64. Sato, H., Macchiarulo, A., Thomas, C., Gioiello, A., Une, M., Hofmann, A. F., Saladin, R., Schoonjans, K., Pellicciari, R., and Auwerx, J. (2008). Novel potent and selective bile acid derivatives as TGR5 agonists: Biological screening, structure-activity relationships, and molecular modeling studies. J. Med. Chem. 51, 1831-1841
65. Sberna, A. L., Assem, M., Gautier, T., Grober, J., Guiu, B., Jeannin, A., Pais de Barros, J. P., Athias, A., Lagrost, L., and Masson, D. (2011). Constitutive androstane receptor activation stimulates faecal bile acid excretion and reverse cholesterol transport in mice. J. Hepatol. 55, 154-161
66. Shiau, Y. F. (1990). Mechanism of intestinal fatty acid uptake in the rat: The role of an acidic microclimate. J. Physiol. 421, 463-474
67. Slater, T. F., and Delaney, V. B. (1970). Liver adenosine triphosphate content and bile flow rate in the rat. Biochem. J. 116, 303-308
68. Slatter, J. G., Cheng, O., Cornwell, P. D., de Souza, A., Rockett, J., Rushmore, T., Hartley, D., Evers, R., He, Y., Dai, X., et al. (2006). Microarray-based compendium of hepatic gene expression profiles for prototypical ADME gene-inducing compounds in rats and mice in vivo. Xenobiotica 36, 902-937
69. Song, K. H., Li, T., Owsley, E., Strom, S., and Chiang, J. Y. (2009). Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology 49, 297-305
70. Song, P., Zhang, Y., and Klaassen, C. D. (2011). Dose-response of five bile acids on serum and liver bile acid concentrations and hepatotoxicity in mice. Tox. Sci. 123, 359-367
71. Stieger, B., Fattinger, K., Madon, J., Kullak-Ublick, G. A., and Meier, P. J. (2000). Drug-and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 118, 422-430
72. Sueyoshi,.T., Kawamoto, T., Zelko, I., Honkakoski, P., Negishi, M. (1999). The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. J. Biol. Chem. 274, 6043-6046
73. Tabibian, J. H., and Lindor, K. D. (2015). Primary biliary cirrhosis: Safety and benefits of established and emerging therapies. Expert. Opin. Drug Saf. 14, 1435-1444
74. Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J., and Schoonjans, K. (2008). Targeting bile-acid signalling for metabolic diseases. Nat. Rev. Drug Discov. 7, 678-693
75. Trauner, M., Meier, P. J., and Boyer, J. L. (1998). Molecular pathogenesis of cholestasis. N. Engl. J. Med. 339, 1217-1227
76. Tzameli, I., Pissios, P., Schuetz, E. G., and Moore, D. D. (2000). The xenobiotic compound 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene is an agonist ligand for the nuclear receptor CAR. Mol. Cell. Biol. 20, 2951-2958
77. Wagner, M., Halilbasic, E., Marschall, H. U., Zollner, G., Fickert, P., Langner, C., Zatloukal, K., Denk, H., and Trauner, M. (2005). CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Hepatology 42, 420-430
78. Wang, D. Q., Tazuma, S., Cohen, D. E., and Carey, M. C. (2003). Feeding natural hydrophilic bile acids inhibits intestinal cholesterol absorption: Studies in the gallstone-susceptible mouse. Am. J. Physiol. Gastrointest. Liver Physiol. 285, G494-G502
79. Wang, R., Salem, M., Yousef, I. M., Tuchweber, B., Lam, P., Childs, S. J., Helgason, C. D., Ackerley, C., Phillips, M. J., and Ling, V. (2001). Targeted inactivation of sister of P-glycoprotein gene (spgp) in mice results in nonprogressive but persistent intrahepatic cholestasis. Proc. Nat. Acad. Sci. USA. 98, 2011-2016
80. Watanabe, M., Houten, S. M., Mataki, C., Christoffolete, M. A., Kim, B. W., Sato, H., Messaddeq, N., Harney, J. W., Ezaki, O., Kodama, T., et al. (2006). Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439, 484-489
81. Westergaard, H., and Dietschy, J. M. (1976). The mechanism whereby bile acid micelles increase the rate of fatty acid and cholesterol uptake into the intestinal mucosal cell. J. Clin. Invest. 58, 97-108
82. Xie, M. H., Holcomb, I., Deuel, B., Dowd, P., Huang, A., Vagts, A., Foster, J., Liang, J., Brush, J., Gu, Q., et al. (1999). FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 11, 729-735
83. Yamakawa, T., Takano, T., Utsunomiya, H., Kadonosono, K., and Okamura, A. (2007). Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia. Endocr. J. 54, 53-58
84. Zhang, W., Jha, P., Wolfe, B., Gioiello, A., Pellicciari, R., Wang, J., Heubi, J., and Setchell, K. D. (2015). Tandem mass spectrometric determination of atypical 3beta-hydroxy-Delta5-bile acids in patients with 3beta-hydroxy-Delta5-C27-steroid oxidoreductase deficiency: Application to diagnosis and monitoring of bile acid therapeutic response. Clin. Chem. 61, 955-963
85. Zhang, Y., and Klaassen, C. D. (2010). Effects of feeding bile acids and a bile acid sequestrant on hepatic bile acid composition in mice. J. Lipid Res. 51, 3230-3242
86. Zieve, F. J., Kalin, M. F., Schwartz, S. L., Jones, M. R., and Bailey, W. L. (2007). Results of the glucose-lowering effect of WelChol study (GLOWS): A randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin. Ther. 29, 74-83